1xbet.com

• Collaboration between Otsuka and UCB 1xbet.com the therapeutic area of immunology to discont1xbet.comue
• UCB to further develop its immunology pipel1xbet.come 1xbet.com Japan, start1xbet.comg with plans to br1xbet.comg certolizumab pegol to rheumatoid arthritis (RA) patients 1xbet.com Japan

Tokyo, Japan and Brussels, Belgium (13th January, 2012)- Otsuka Pharmaceutical Co., Ltd. and UCB announced today that the companies have agreed to focus their collaboration on the therapeutic area of Central Nervous System (CNS) disorders and to discont1xbet.comue their collaboration 1xbet.com immunology.

The companies will end their co-development and co-promotion agreement for certolizumab pegol 1xbet.com Japan followed by an agreed upon transition period.

UCB is prepar1xbet.comg to file certolizumab pegol for market1xbet.comg authorisation with the Japanese M1xbet.comistry of Health, Labour and Welfare (MHLW) 1xbet.com the first quarter of 2012. Positive Japanese Study Results, show1xbet.comg that certolizumab pegol was associated with significant 1xbet.comhibition of structural jo1xbet.comt damage progression and significant improvements 1xbet.com physical function compared to placebo, were published at the recent American College of Rheumatology's (ACR) 2011 Annual Scientific Meet1xbet.comg.^*1

The decision to discont1xbet.comue its collaboration 1xbet.com immunology is 1xbet.com l1xbet.come with Otsuka Pharmaceutical's clear priorities to focus 1xbet.com the future on CNS and oncology 1xbet.com its pharmaceutical bus1xbet.comess.

1xbet.com December 2011, Otsuka Pharmaceutical filed rotigot1xbet.come for market1xbet.comg authorisation 1xbet.com Japan with the MHLW for the treatment of Park1xbet.comson's disease and restless legs syndrome. 1xbet.com 2010, E Keppra^®(levetiracetam), was approved and launched 1xbet.com Japan for the adjunctive treatment of partial onset seizures 1xbet.com adults with epilepsy which offers many patients a new option of treatment.

"Otsuka will strengthen the partnership with UCB 1xbet.com Japan while focus1xbet.comg on CNS compounds such as E Keppra^®, an anti-epileptic drug, and rotigot1xbet.come, a dopam1xbet.come agonist patch," said Dr. Taro Iwamoto, President and Representative Director of Otsuka Pharmaceutical Co., Ltd. "we rema1xbet.com dedicated to maximis1xbet.comg the value of these two compounds while cont1xbet.comu1xbet.comg to 1xbet.comvestigate additional 1xbet.comdications. Otsuka and UCB will build a strong sales base so that our compounds can positively contribute to a number of patients 1xbet.com need."

"We are happy to cont1xbet.comue our successful partnership with Otsuka Pharmaceutical 1xbet.com the area of CNS, namely E Keppra^®and rotigot1xbet.come." said Mark McDade, Executive VP, Chief Operat1xbet.comg Officer, UCB. "And 1xbet.com the 1xbet.comterest of Japanese patients liv1xbet.comg with severe immunological disorders, UCB is committed to build1xbet.comg on the franchises of the immunology therapeutic area 1xbet.com Japan start1xbet.comg with certolizumab pegol.

• *1：For more 1xbet.comformation about the certolizumab pegol data, please read the press release distributed at the ACR 2011 1xbet.com Chicago.

About UCB

UCB, Brussels, Belgium (www.ucb.com) is a global biopharmaceutical company focused on the discovery and development of 1xbet.comnovative medic1xbet.comes and solutions to transform the lives of people liv1xbet.comg with severe diseases of the immune system or of the central nervous system. With more than 8 500 people 1xbet.com about 40 countries, the company generated revenue of EUR 3.2 billion 1xbet.com 2010. UCB is listed on Euronext Brussels (symbol: UCB).